



CERTIFICATE OF MAILING
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED
WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT
POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:
COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231,

ON April 22, 2003

Kathleen L. Seibert

April 22, 2003
DATE

16254
RECEIVED
APR 25 2003
TECH CENTER 1600/2900

11/ B + Prior
Art w/att
c/m
4-22-03

Attorney Docket No.: P32286

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Blackler, et al.

April 22, 2003

Appln. No.: 10/019,355

Group Art Unit: 1625

Filed: March 22, 2002

Examiner: B.M. Robinson

For: THIAZOLIDINEDIONE DERIVATIVE AND ITS USE AS ANTIDIABETIC

Commissioner for Patents
Washington, D.C. 20231

Best
5-30-03

AMENDMENT AND INFORMATION DISCLOSURE STATEMENT

Sir:

In response to the Office Action dated October 22, 2002, please amend the
above-identified application as follows:

In the claims:

Kindly cancel claims 1-8 and 12, without prejudice or disclaimer.

Please add claims 13-23 as follows:

13. (New) A compound, 5-[4-[2-(N-methyl-N-(2-pyridylamino)ethoxy)benzyl]thiazolidine-2,4-dione, hydrochloride dihydrate, wherein said compound provides at least one of:

(i) an infrared spectrum containing peaks at 3392, 2739, 1751, 1325 and 713
cm⁻¹; and

(ii) an X-ray powder diffraction pattern containing peaks at 9.1, 12.0, 15.7, 16.3
and 19.8 °2θ.

04/24/2003 GWORDDF1 00000034 192570 10019355
01 FC:1806 180.00 CH

04/24/2003 GWORDDF1 00000034 192570 10019355
03 FC:1202 36.00 CH